TB-500 is one of the few research peptides whose name points at a molecule it is not. The label belongs to a synthetic peptide of seven residues. Almost all of the biology quoted alongside it belongs to a 43-residue protein that contains those seven residues in the middle. The two differ by more than four thousand daltons, and the literature moves between them without always flagging the switch. This article separates them, states the chemistry of the material in the vial, and sets out what the work supports.
Thymosin beta-4, the parent protein
Thymosin beta-4 is a 43-residue protein found in most mammalian cell types and present at high concentration in platelets and in wound fluid. It is not a thymic hormone in the classical sense despite the name, which is an artefact of where the original preparations were isolated. Its principal established function is as the main intracellular actin-sequestering molecule. It binds monomeric G-actin one to one and holds it out of the polymerisation pool, giving a cell a reservoir of monomer it can release when it needs to build filaments quickly.
That single function explains why the protein turns up in so many research areas. Anything that depends on rapid cytoskeletal remodelling depends on the available monomer pool, and that includes cell migration, cell shape change, and the reorganisation that follows tissue injury.
The actin-binding site at residues 17 to 23
Inside those 43 residues sits a short central stretch, Leu-Lys-Lys-Thr-Glu-Thr-Gln, written LKKTETQ, spanning positions 17 to 23. This is the actin-binding site of the parent protein, and the motif is conserved across the beta-thymosin family. Structural and truncation work assigns the contact with G-actin to this region, which is why a short synthetic version of it exists at all.
It is worth being precise about how much that establishes. The segment is where the contact is made, but the binding affinity and the full behaviour of the intact protein are not reproduced by the isolated stretch. Flanking residues and the helical character of the intact chain both contribute.
What TB-500 actually is
TB-500 is the synthetic, N-terminally acetylated copy of that segment. The sequence is Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, a heptapeptide. CAS 885340-08-9, formula C38H68N10O14, average molecular weight 889.02. Seven residues, no disulfide bridge, no cyclisation, no methionine and no cysteine. The acetyl cap removes one positive charge from the N-terminal amine and blunts aminopeptidase attack at that end.
The clearest published definition comes from doping control rather than from cell biology. Ho and colleagues characterised TB-500 in equine urine and plasma by liquid chromatography mass spectrometry in 2012 and describe it explicitly as the acetylated heptapeptide corresponding to the active region of thymosin beta-4. That paper states the molecule the analytical community detects under the name.
One caution follows. Some suppliers attach the name TB-500 to full-length thymosin beta-4, CAS 77591-33-4, average mass near 4963, one methionine in the chain. That is a different material with a different analytical signature. The vial supplied here is the heptapeptide, and any identity check should be made against 889.02.
Parent protein versus fragment
| Thymosin beta-4 | TB-500 as supplied | |
|---|---|---|
| Length | 43 residues | 7 residues |
| Identity | CAS 77591-33-4, average mass near 4963 | CAS 885340-08-9, C38H68N10O14, 889.02 |
| Origin | Endogenous, present in most cell types | Solid-phase synthesis, acetylated at the N-terminus |
| Actin binding | One-to-one sequestration of G-actin, well characterised | Carries the binding motif, affinity not equivalent |
| Literature depth | Large, spanning three decades | Thin, largely analytical and veterinary |
| Synthesis | 43 couplings, a demanding target | 7 couplings, a straightforward target |
The published record mostly belongs to the parent
Nearly all the biology quoted next to a TB-500 vial is parent-protein work and should be read that way. The actin-sequestering identity (Safer, 1991), the rodent dermal reports (Malinda, 1999), the corneal work (Sosne, 2002), the cardiac migration and integrin-linked kinase account (Bock-Marquette, 2004) and the review that carried the field into wider circulation (Goldstein, 2005) all used the 43-residue protein or a recombinant version of it. None of them tested the acetylated heptapeptide.
The fragment has a much thinner record of its own. It consists mainly of the analytical chemistry that defines and detects it, regulatory work in equine and human sport where it is listed as a prohibited substance, and a small set of reports in which short LKKTET-containing peptides retained some actin-related activity in cell assays. A design built on the fragment should acknowledge that most of the supporting literature is inferential, carried across from a larger molecule.
What the parent-protein models show
- Cell migration. Increased migration of endothelial cells, keratinocytes and fibroblasts in culture, measured by scratch closure and transwell assays. This follows most directly from the actin biology.
- Dermal models. Rodent studies reporting faster closure and increased vessel density against controls, with changes in the inflammatory profile of the wound bed.
- Corneal models. Ophthalmic work reporting effects on corneal epithelial repair and on inflammatory markers in the eye.
- Cardiac models. Cell migration and survival after experimental injury in mice, the reason the molecule appears in cardiovascular reviews.
The unifying theme is cell movement into a space that was damaged. That is the limit of what the work supports, and it describes cell and rodent models of a 43-residue protein.
Synthesis, purity and identity
A heptapeptide is one of the easier targets in solid-phase synthesis. Seven couplings leave far less room for deletion sequences than a long chain does, and the crude material is usually clean enough that a single reversed-phase purification reaches a high figure. High HPLC purity here is the expectation rather than an achievement, and a low number on a seven-residue sequence is a warning sign rather than something chain length excuses.
Identity is the line that does the real work here. At 889.02 the heptapeptide sits far from the parent protein, so one mass-spectrometry reading settles which material is in the vial. Ask for the observed mass, not only a purity percentage. With neither methionine nor cysteine in the sequence, oxidation is not the failure mode to plan around. The peptide is short, charged and hygroscopic, so moisture is the variable to control. Our article on what HPLC purity measures covers how to read a chromatogram, and the COA guide covers identity confirmation by mass spectrometry.
Formats a lab can order
The single compound sits in the peptides collection. It is also a component in two co-lyophilized vials, the Wolverine Blend and the GLOW blend, where the label states each component in milligrams. The BPC-157 pairing is covered in a separate article, and the multi-component vials in GLOW versus KLOW.
Frequently asked questions
Is TB-500 the same molecule as thymosin beta-4?
No. TB-500 is the acetylated heptapeptide Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln at 889.02 daltons, residues 17 to 23 of the parent. Thymosin beta-4 is the complete 43-residue protein near 4963 daltons. Literature on one should not be assumed to apply to the other, and mass tells them apart immediately.
What does actin sequestering mean in practice?
The parent protein binds a single unit of monomeric actin and keeps it from joining a growing filament. The bound monomer becomes a reserve the cell can draw on, which is what links the protein to rapid cytoskeletal remodelling and to cell migration.
What mass should a certificate report for TB-500?
889.02 as the average molecular weight, for the formula C38H68N10O14. The observed figure should agree within the stated tolerance of the method. A reading near 4963 means the certificate describes the full-length parent protein and not the heptapeptide.
References
- Safer D, Elzinga M and Nachmias VT, 1991. Journal of Biological Chemistry. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable.
- Malinda KM and colleagues, 1999. Journal of Investigative Dermatology. Thymosin beta4 accelerates wound healing.
- Bock-Marquette I and colleagues, 2004. Nature. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair.
- Goldstein AL, Hannappel E and Kleinman HK, 2005. Trends in Molecular Medicine. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues.
- Ho EN and colleagues, 2012. Journal of Chromatography A. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta 4, in equine urine and plasma by liquid chromatography mass spectrometry.
Research use only. This article summarises laboratory and preclinical literature. Homegrown Peptides products are not for human or animal use, are not drugs, and are not intended to diagnose, treat, cure or prevent any disease. Nothing here is medical advice.
